Cargando…
Immunosedation: a consideration for sepsis
In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agent...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784358/ https://www.ncbi.nlm.nih.gov/pubmed/19889196 http://dx.doi.org/10.1186/cc8034 |
_version_ | 1782174731488722944 |
---|---|
author | MacLaren, Robert |
author_facet | MacLaren, Robert |
author_sort | MacLaren, Robert |
collection | PubMed |
description | In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agents significantly reduced short-term mortality compared with saline. This study, in addition to those by others, suggests there are disparate immunomodulating effects between sedatives. Clinical studies are warranted to investigate whether these effects impact outcomes of septic patients. Perhaps one day the choice of sedative in septic patients will not be based solely on sedative properties but rather immunosedative profiles. |
format | Text |
id | pubmed-2784358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27843582010-10-06 Immunosedation: a consideration for sepsis MacLaren, Robert Crit Care Commentary In a recent issue of Critical Care, Qiao and colleagues showed in a rat model of sepsis that dexmedetomidine and midazolam suppress the generation of pro-inflammatory mediators but the effects vary between agents. While dexmedetomidine limited apoptosis to a greater extent than midazolam, both agents significantly reduced short-term mortality compared with saline. This study, in addition to those by others, suggests there are disparate immunomodulating effects between sedatives. Clinical studies are warranted to investigate whether these effects impact outcomes of septic patients. Perhaps one day the choice of sedative in septic patients will not be based solely on sedative properties but rather immunosedative profiles. BioMed Central 2009 2009-10-06 /pmc/articles/PMC2784358/ /pubmed/19889196 http://dx.doi.org/10.1186/cc8034 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Commentary MacLaren, Robert Immunosedation: a consideration for sepsis |
title | Immunosedation: a consideration for sepsis |
title_full | Immunosedation: a consideration for sepsis |
title_fullStr | Immunosedation: a consideration for sepsis |
title_full_unstemmed | Immunosedation: a consideration for sepsis |
title_short | Immunosedation: a consideration for sepsis |
title_sort | immunosedation: a consideration for sepsis |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784358/ https://www.ncbi.nlm.nih.gov/pubmed/19889196 http://dx.doi.org/10.1186/cc8034 |
work_keys_str_mv | AT maclarenrobert immunosedationaconsiderationforsepsis |